Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients
NCT01493154
Terminated
This study will test the safety of an HPV DNA vaccine after it is injected into your muscle using an electroporation device (TriGridTM Delivery System made by Ichor Medical Systems), and will test the ability of the vaccine to help your body's immune system to recognize HPV-infected and associated cancer cells. In addition to giving the vaccine using an electroporation device, we are giving the vaccine in combination with an immunomodulatory agent to further enhance immune responses against HPV-... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/20/2018
Locations: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Head and Neck Cancer
Register for Updates
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
NCT03438344
Withdrawn
This randomized phase II trial studies how well multi-antigen cytomegalovirus (CMV)-modified vaccinia Ankara vaccine works in reducing CMV related complications in patients with blood cancer who are undergoing donor stem cell transplant. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill cancer cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2018
Locations: City of Hope Medical Center, Duarte, California +2 locations
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Bone Marrow Transplantation Recipient, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic Cell Transplantation Recipient, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Register for Updates
Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer
NCT00640861
Completed
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known which vaccine is most effective in treating breast cancer. PURPOSE: This randomized clinical trial is studying the side effects of three different vaccine therapies and comparing the vaccines to see how well they work in treating patients with previously treated stage II or stage III breast cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/29/2018
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Breast Cancer
Register for Updates
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers
NCT03191383
Withdrawn
The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the investigational GSK RSV vaccine in pregnant women aged 18 to 40 years and infants born to the vaccinated women
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
10/12/2018
Locations: GSK Investigational Site, Newton, Kansas +11 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Pilot Study of DRibble Vaccine for Prostate Cancer Patients
NCT02234921
Completed
This is a pilot study of the DRibble vaccine in patients with advanced prostate cancer.
Gender:
MALE
Ages:
All
Trial Updated:
10/09/2018
Locations: Providence Health & Services, Portland, Oregon
Conditions: Adenocarcinoma of the Prostate
Register for Updates
Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant
NCT02957656
Completed
The purpose of this study is to evaluate the safety and immunogenicity of one dose of H7N9 pandemic live attenuated influenza vaccine (H7N9 pLAIV) followed by AS03-adjuvanted H7N9 pandemic inactivated influenza vaccine (H7N9 pIIV).
Gender:
ALL
Ages:
Between 20 years and 49 years
Trial Updated:
10/01/2018
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Influenza A Virus, H7N9 Subtype
Register for Updates
Systems Biology of PNEUMOVAX®23 and PREVNAR 13®
NCT01307449
Completed
Vaccination is the most effective way of preventing infectious diseases. Despite the success of vaccines in general, vaccines induce diminished antibody responses and lower protection in the elderly in particular. This could be explained by a defect in the early responses of an ageing immune system. A better understanding of the basic immunological mechanisms that mediate vaccine efficacy is incomplete. Such information is critical and could greatly decrease both the cost and the time to new vac... Read More
Gender:
ALL
Ages:
Between 25 years and 89 years
Trial Updated:
09/28/2018
Locations: Hope Clinic of the Emory Vaccine Center, Decatur, Georgia +1 locations
Conditions: Pneumococcal Infection
Register for Updates
Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
NCT00024466
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vaccines made from a person's cancer cells may make the body build an immune response to kill cancer cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Combining chemotherapy with vaccine therapy and peripheral stem cell transplantation may be effective in treating multiple myeloma. PURPOSE: Phase I/II trial to... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
09/17/2018
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Multiple Myeloma
Register for Updates
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life
NCT01214837
Completed
The purpose of this study was to assess immunogenicity of a 3-dose versus 4-dose infant vaccination schedule including kinetics of immune response in the early phases of the series.
Gender:
ALL
Ages:
Between 55 days and 89 days
Trial Updated:
09/10/2018
Locations: Not set, Birmingham, Alabama +39 locations
Conditions: Meningococcal Disease, Meningococcal Meningitis
Register for Updates
Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy
NCT01695733
Terminated
This clinical trial studies the best time to administer the influenza vaccine to patients with non-hematologic malignancies receiving chemotherapy. Giving the vaccine at different times relative to chemotherapy may affect how well it works to help the body build an immune response and prevent influenza in these patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2018
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Neoplasms
Register for Updates
Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)
NCT01924169
Terminated
The goal of this clinical research study is to learn if lenalidomide can increase the level of immunoglobulins (parts of the blood that may help to improve the immune system's function) and/or will improve the protective effect of the flu and pneumonia vaccines in patients with CLL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/24/2018
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Hematologic Disorder
Register for Updates
Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014
NCT00614614
Completed
The purpose of the study is to characterize the immunogenicity \& safety of a booster dose of GSK Biologicals' meningococcal vaccine 134612 given at 12-15 months of age or at 15-18 months of age (co-administered with Infanrix®) in healthy toddlers primed with GSK Biological's Hib-meningococcal vaccine 792014. This study is single-blinded for the primary phase and open-label for the booster phase.
Gender:
ALL
Ages:
Between 6 weeks and 12 weeks
Trial Updated:
08/22/2018
Locations: GSK Investigational Site, Birmingham, Alabama +55 locations
Conditions: Infections, Meningococcal
Register for Updates